Some biomarkers show potential in predicting tumor response to neoadjuvant chemoradiotherapy in rectal cancer: CIN appears to be associated with a good response, whereas TP53 and KRAS are associated with a poor response. This evidence concerns the gene KRAS and neoplasm.